D espite advances in the management of multiple myeloma in the past few decades, it remains an incurable disease. Conventional treatments achieve a median survival of 3 to 5 years. 1, 2 The disease follows a relapsing course in the majority of patients, regardless of treatment regimen or initial response to treatment. Recently, the management of patients with multiple myeloma has been transformed by the introl l duction of three novel agents: thalidomide, lenalidol l mide and bortezomib. These three agents represent a new generation of therapies for multiple myeloma that affect both specific intracellular signaling pathways within the tumor cell and also target the tumor microl l environment. This article describes the pivotal trials that have led to the incorporation of these novel agents in the frontline setting.
Traditionally, newly diagnosed myeloma patients have been classified as either transplant or nonltransl l plant candidates. This classification has been based on a number of factors including age, performance status, colmorbid medical conditions, and patient preference. Induction therapy regimens are often decided by a patient' s potential transplant status. Transplant candil l dates were typically treated with nonlalkylating agents to prevent marrow damage. Nonltransplant candidates often received alkylatinglagent based therapy.
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Herbert H. Loong from the the department of clinical oncology, the chinese university of hong Kong correspondence: herbert h. loong md · department of clinical oncology, the chinese university of hong Kong, prince of Wales hospital · 30-32 ngan shing street, shatin, new territories hong Kong · t: +8522-632-2160 f: +8522-632-2160 · h_loong@clo.cuhk.edu.hk · accepted for publication september 2008 hematol oncol stem cel ther 2008; 1(4): 201-209 significant advances in our understanding of the biology of multiple myeloma have led to exciting new opportunities in treatment. the management of this disease is rapidly changing with a plethora of clinical trials initiated with novel agents, namely thalidomide, lenalidomide and bortezomib, either alone or in conjunction with established modalities such as conventional cytotoxic agents and stem-cell transplan-tation. the combination of these novel agents together with conventional regimens have led to higher response rates and survival, providing options for patients whose disease is otherwise resistant to con-ventional therapy. these pivotal trials that lead to the approval of these three novel agents in treatment naïve patients. the potential implications in the frontline treatment paradigm of multiple myeloma are discussed.
For those patients preselected for autologous stem cell transplantation (ASCT), the degree of clinical rel l sponse was never as important as whether or not they actually proceeded to transplant. However, the achievel l ment of complete response (CR) after induction theral l py is now believed to be a strong predictor of longlterm survival. 3 Unfortunately, traditional induction regimens only achieved a limited number of CR or near complete (nCR) treatment responses in the range of 3% to 7%. 4l 8 In the interim analysis of the currently active multil center Intergroupe Francophone du Myelome (IFM) 2005l01 study conducted in Europe, Harousseau et al reported a modest CR/nCR rate at 9% only in the control arm of vincristine, doxorubicin and dexamethal l sone (VAD). 8 There is clearly a need for improvement in induction therapy response. Emerging studies have shown that the incorporation of novel agents into tradil l tional induction regimens can improve CR/nCR rates (Table 1) .
Thalidomide
Thalidomide has been widely used in patients with rel l lapsed or refractory multiple myeloma for a number of years. Following the initial report of singlelagent activl l ity in 1999, 9 thalidomide has since become one of the most widely used drugs to treat multiple myeloma in the relapsed/refractory setting. The FDA has approved its use in combination with highldose dexamethasone as treatment of newly diagnosed multiple myeloma.
Thalidomide combinations in the frontline setting
The approval of thalidomide plus dexamethasone in the frontline setting was based on the results of Eastern Cooperative Oncology Group (ECOG) trial E1A00. 4 This was a randomized, controlled phase III trial coml l paring thalidomide 200 mg daily PO plus highldose dexamethasone at 40 mg daily on days 1l4, 9l12, 17l 20 (Thal/Dex) repeated monthly for 4 cycles. The control arm received high doseldexamethasone alone. In total, 207 patients were recruited into the trial. It is noteworthy that no specific thromboprophylaxis was mandated in this study.The response rate with thalidol l mide plus dexamethasone was significantly higher than with dexamethasone alone (63% v 41%, respectively; P=.0017). Complete responses occurred in 4% of pal l tients within four cycles of therapy with Thal/Dex, and in 0% of patients in the dexamethasonelalone arm. Disease progression within four cycles of therapy was noted in 2% of patients with Thal/Dex and 5% of patients with dexamethasone alone. However, this regimen was associated with a significant incidence of deep venous thrombosis (DVT), requiring the use of anticoagulants like warfarin or low molecular weight heparin (LMWH). The incidence rates of grade 3 or higher DVT, rash, bradycardia, neuropathy, and any grade 4 to 5 toxicity in the first 4 months were signifil l cantly higher with thalidomide plus dexamethasone compared with dexamethasone alone (45% vs. 21%, respectively; P<.001). This study was also not powered to look at overall survival.
Based on a design similar to the ECOG E1A00, an extended study was performed by Rajkumar et al. Known as MM 003, 10 this phase III trial followed a similar design of 4 cycles of ThallDex vs. dexamethal l sone alone. Patients were then subsequently placed on maintenance dexamethasone 40 mg on days 1l4 every 28 days until progression. More than 400 patients have been recruited with specific endlpoints looking at timeltolprogression (TTP), overall survival (OS), relal l tive response (RR) and most importantly safety issues. Using intentionltoltreat analysis, the medianlTTP for Thal/Dex was 22.4 months compared with 6.5 months for dexamethasone alone (P<.0001). Median OS of the dexamethasonelalone arm was 32 months and the OS for the Thal/Dex group had not been reached yet as of the time of writing. Increased toxicities in the combination Thal/Dex arm in particular in the form of thrombotic events were reconfirmed ( Table 2) .
Thalidomide plus dexamethasone versus VAD as ind d duction treatment
A randomized trial compared Thal/Dex with vincrisl l tine/doxorubicin/dexamethasone (VAD) as an inducl l tion regimen prior to ASCT in newly diagnosed mull l tiple myeloma patients up to 65 years of age. 11 Since 2003, 204 patients were randomly assigned to receive a 4lmonth treatment with Thal/Dex (n=100) or a VADl like regimen (n=104). All patients were intended to proceed to peripheral blood stem cell (PBSC) mobilil l zation and to receive highldose therapy with melphalan 200 mg/m 2 (MELl200) and autologous PBSC support. The main characteristics of patients in each arm were similar. In both arms, 91% of patients proceeded to PBSC mobilization, PBSC harvests were similarly sucl l cessful, and 83% of patients received highldose therapy and ASCT. Very good partial response (VGPR, defined by serum and urine Mlprotein detectable by immunol l fixation but not on electrophoresis or 90% or greater reduction in serum Mlprotein plus urine Mlprotein level <100mg per 24 h) rates were significantly higher in the Thal/Dex arm before PBSC collection (25% vs. 6%, P=.0027) and before highldose therapy and ASCT . This study confirms that Thal/Dex is an effective firstlline treatment for multiple myeloma and supports its use as an induction regimen, which could be preferred to infusions of VAD in candil l dates for highldose therapy.
Thalidomide and melphalan and prednisolone (MPT) in the elderly population
Although autologous stemlcell transplantation (autol SCT) has been associated with longer progressionlfree survival, many patients diagnosed with myeloma are elderly with colmorbid conditions which may render them unfit for autolSCT. For these patients, the stanl l dard treatment has been combination melphalan/predl l nisolone (MP) without stem cell transplantation. Palumbo et al 5 looked at the addition of thalidomide to melphalan and prednisolone (MPT) in a phase III trial involving an elderly patient population older than 65 years of age. The rate of complete responders qual l drupled from 7% with MP to 28% with MPT with an increase in the overall response rate from 48% to 76%. Median progressionlfree survival also increased from 14 months to 33 months and 2lyear event free survival improved from 27% to 54% in favor of the tripleldrug arm (Hazard ratio for MPT 0.51, 95% CI 0.35l0.75, P=.0006). There was also a trend towards improved overall survival rate at 3 years of 64% in the MP alone compared to 80% for the MPT arm.
In (Table 3) .
Thalidomide, thromboembolism and thromboprophyd d laxis
Although venous thromboembolism is a common coml l plication in cancer patients, therapy with thalidomide combinations appears to substantially increase this risk. 4, 13 Prophylaxis with therapeutic doses of warfarin or lowlmolecular weight heparin (LMWH) has been advised, 13, 14 while aspirin may also reduce the risk of venous thromboembolic events. However, it has been suggested that this should only be reserved for patients unable or unwilling to take warfarin or LMWH. As these studies were performed in the West, whether the thromboembolic risk is equally as high in our predomil l nantly nonlCaucasian population has yet to be valil l dated. 
Other side effects of thalidomide
Aside from the potential of thromboembolism menl l tioned previously, the most common adverse events associated with thalidomide treatment are constipal l tion, fatigue, somnolence and peripheral neuropathy. 9, 15 Peripheral neuropathy is a common adverse event that often limits the dose and duration of treatment. In a retl l rospective analysis of a phase II Mayo Clinic trial, 16 56% of patients were identified as having developed sympl l toms of peripheral neuropathy. Neuropathy improved in 27% during the treatment phase with/without dose reduction or after cessation of thalidomide. Fifteen percent of patients worsened despite dose reduction or stopping thalidomide while 52% remained stable durl l ing treatment. Most patients experienced grade 1 neul l ropathy only, but 11% of all patients had grade 2 neul l ropathy and 2% had grade 3 neuropathy. Predominant symptoms of neuropathy were tingling and numbness involving both the upper limb and lower limbs. Small subsets of patients complained of hearing loss and erecl l tile dysfunction. In view of the toxicity profile of thal l lidomide, its analogue lenalidomide was developed with the aim of retaining its clinical efficacy but improving the toxicity profile.
Lenalidomide (Revlimid)
Lenalidomide belongs to a class of drugs known as IMiDs (immunomodulatory drugs) that are structurl l ally related to thalidomide, but have relatively increased potency and differing side effect profiles. Results from phase I and II studies have shown lenalidomide to have significant and durable singlelagent activity in the rel l lapsed setting with responses seen in 14% to 29% of patients. 17, 18 When combined with dexamethasone in a phase III randomized study involving more than 140 relapsed or refractory multiple myeloma patients, Weber et al 19 demonstrated greater efficacy in the lenalidomide plus dexamethasone group compared with dexamethasone alone, achieving a response rate of 59% vs. 21% (P<.001) and a CR rate of 13% vs. <1% (P<.001). With these enl l couraging results, lenalidomide has been investigated in the upfront setting.
Lenalidomide combinations in the frontline setting
Phase II studies have investigated the use of lenalidol l mide combinations in newly diagnosed multiple myl l eloma. In 34 newly diagnosed multiple myeloma pal l tients, Macy et al 20 demonstrated an astonishing overall response rate of 90% at 4 months with 48% of patients achieving CR or VGPR. Ninety percent of patients rel l mained alive after 2 years and the 2lyear PFS was 59%. Aspirin was an effective DVT prophylaxis.
Under the auspices of ECOG, Rajkumar et al furl l ther investigated first line use of lenalidomide and dexamethasone in a phase III setting. 21 ECOG E4A03 compared high dose dexamethasone (i.e. standard dose at 480 mg/cycle) vs. low dose dexamethasone (i.e. 160 mg/cycle) in combination with lenalidomide. More than 400 patients had been recruited at the time of writing. At the second prelplanned interim analysis presented at the American Society of Hematology (ASH) Meeting in 2007, OS was significantly superior with the lenalidl l omide plus low dose dexamethasone arm compared to the lenalidomide plus high dose dexamethasone arm, with a 1lyear survival at 96% vs. 87% (P<.001), respecl l tively. The 18lmonth survival rate was 91% versus 80%, respectively.
Although there was a significantly greater incidence of DVT/pulmonary embolism in the highldose arm (18.4% vs. 6.3%, P<.001), further analysis of the data showed that the poorer overall survival of the highl dose dexamethasone arm could not be explained by this adverse event alone. The increased mortality in the highldose dexamethasone group was due to disease progression (myeloma deaths) as well as increased toxl l icity. Thus, the study has major implications for the use of highldose dexamethasone in the treatment of newly diagnosed multiple myeloma (Table 4) .
Clinical trials are currently being performed assessl l ing lenalidomide in combination with other agents. Lenalidomide and melphalan/prednisolone has been investigated in elderly patients with newly diagnosed multiple myeloma. 22 Preliminary results show that the combination produces at least a partial response in 81% of patients with 47.6% of patients achieving VGPR and 24% achieving CR. Hematologic adverse events were frequent but noted as manageable. Nonlhematologic adverse events were low. Aspirin appeared to provide adequate antilthrombosis prophylaxis.
Side effects of lenalidomide
Studies show that lenalidomide is better tolerated than thalidomide in several aspects of its toxicity prol l file. Clinically significant somnolence, constipation and neuropathy rarely occurred in prior studies. Myelosuppression, mainly in the form of neutropenia and thrombocytopenia are the most common grade ≥ 3 toxicities, 18 but are manageable with dose reduction and growth factor support. As seen in thalidomide, the risk of thromboembolic events is also higher in combination with dexamethasone and antilthrombotic prophylaxis is advised.
Bortezomib (Velcade)
Bortezomib is a novel, firstlinlclass proteasome inhibil l tor that has antilproliferative, prolapoptotic, antilanl l giogenic and antiltumor activity through the inhibition of proteasomal degradation of numerous regulatory proteins. 23, 24 Prelclinical studies have demonstrated synergistic or additive antiltumor activity with agents commonly used in the treatment of multiple myeloma. Bortezomib with or without dexamethasone was shown to be active in two phase II studies in patients with relapsed/refractory myeloma. 25, 26 The internationl l al, randomized phase III Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial rel l cruited patients with relapsed multiple myeloma followl l ing 1 to 3 prior therapies. 27 It showed that singlelagent bortezomib provides a significantly longer TTP, higher response rate and superior survival compared with highl dose dexamethasone. The combined complete and parl l tial response rates were 38% for bortezomib and 18% for dexamethasone (P<.001), and the CR rates were 6% and <1%, respectively (P<.001). Median TTP in the bortezomib and dexamethasone groups were 6.22 months (189 days) and 3.49 months (106 days), respecl l tively (hazard ratio, 0.55; P<.001). Substantial activity has also been demonstrated in bortezomiblbased coml l binations in the relapsed/refractory setting.
Bortezomib combinations in the frontline setting
Bortezomiblbased therapies have demonstrated enl l couraging activity in at least 13 studies in the frontline setting, 28 both as induction therapy prior to stem cell transplantation and as therapy for patients not proceedl l ing to, or not eligible for transplant. In total, more than 700 patients involved in these trials have shown high response rates and consistently higher CR/nCR rates than that seen in conventional induction regimens and conventional therapies.
The double regimen of bortezomib plus dexal l methasone has been investigated as induction therapy in at least 3 trials. 29l31 In a singlelarm phase II study, Jagannath et al 29 investigated the use of bortezomib, as a single agent and in combination with dexamethasone in the firstlline setting. Thirtyltwo consecutive patients received bortezomib for a maximum of six 3lweek cyl l cles with oral dexamethasone 40 mg added if a less than a partial response was achieved after two cycles or a less than CR was achieved after four cycles. The response rate (CR+PR) was 88%, with undetectable paraprol l tein (CR) in 6% and paraprotein detected by immunol l fixation only (nCR) in 19%. All 32 patients completed the first two cycles of bortezomib alone, of whom 3% achieved CR, 9% nCR, and 28% PR. Most patients responded within 4 cycles with the medianltimeltolrel l sponse of 1.9 months. It is noteworthy that bortezomib treatment did not affect stem cell mobilization in eight or transplantation in six patients ( Table 5 ).
The IFM 2005l01 is a large randomized phase III trial comparing bortezomib/dexamethasone vs. VAD as induction therapy prior to autologous stemlcell transl l plantation. Involving more than 480 patients, it coml l pleted accrual in January 2007. Interim analysis of the first 220 patients recruited was presented at the ASH Annual Meeting in 2007 in abstract form. 32 Although the difference in achieving "more than partial response" was insignificant between the VAD and the bortezol l mib/dexamethasone arm both at postlinduction and postlASCT, significantly more patients in the bortezol l mib/dexamethasone arm established CR+nCR and VGPR (9% vs. 22%; P=.0085; 24% vs. 50%; P=.001 respectively) at postlinduction. We eagerly await furl l ther results from this trial. Regimens containing bortezomib and doxorubicin have also demonstrated substantial activity. In a phase II study, the combination of bortezomib, doxorubicin and dexamethasone (PAD) 33 yielded a response rate of 95%, including a 29% CR/nCR rate, prior to steml cell transplantation (SCT). This high response rate was sustained even after SCT and is important as CR status following SCT is associated with longer overall survival time. 34, 35 The efficacy of bortezomib and pel l gylated liposomal doxorubicin (PLD; Doxil) has been validated in a randomized phase III international trial in the refractory or relapsed setting. 36 Median timel tolprogression was increased from 6.5 months for bortezomib to 9.3 months with the PLD+bortezomib combination (P=.000004; hazard ratio, 1.82 [monol l therapy v combination therapy]; 95% CI, 1.41 to 2.35) but as yet, no survival advantage has been demonstratl l ed to date.
In June 2008, based on the pivotal phase III VISTA trial 37 involving 682 patients, bortezomib was approved by the FDA in combination with melphalan and predl l nisolone in the frontline setting for patients who are ineligible for SCT. This phase III multilcenter open lal l bel study randomized patients to receive bortezomib in addition to melphalan and prednisolone (VMP) verl l sus a control group of the dual combination of melphal l lan and prednisolone (MP). Interim analysis showed Median duration of response was 24 months for pal l tients with a CR after VMP, compared with 13 months after MP; the timeltoldisease progression was 24 months and 17 months (P=.0000001), respectively. In addition, the tripleldrug combination demonstrated a statistically significant improvement in OS, with a 40% reduction in the risk for death (P=.0078).
Side effects of bortezomib
Most common toxicities associated with bortezomib treatment include fatigue, gastrointestinal events and peripheral neuropathy. The most commonly reported grade ≥3 toxicities are peripheral neuropathy and myl l elosuppression with anemia, thrombocytopenia and neutropenia. Bortezomiblrelated peripheral neuropal l thy is an important dosellimiting toxicity, 38 but was shown to be reversible in the majority of patients. Based on the earlier two phase II trials of bortezomib in the refractory setting, 25,26 a dose modification guideline in the event of neuropathy has been developed (Table 6) .
Conclusions
Prior to the advent of these novel agents, extensive work performed by the French IFM group and Barlogie et al 39 advocated tandem stemlcell transplants as the standard of care to achieve a higher CR rate, especially in the younger population. However, with the availability of novel agents, the treatment paradigm of multiple myl l eloma has changed dramatically. With the introduction of these therapies in the firstlline treatment setting, the number of objective responses has increased dramatil l cally and consistently, as has the number of complete responses. The results indicate that combining a novel agent with standard chemotherapy increases the numl l ber of complete and near complete responders to 20% or 30%, a number that was previously unheard of outside of a transplant. Notably, this is usually achieved withl l out compromising the dose of either the novel agent or standard chemotherapy. In view of these encouragl l ing results, the role of autologous stemlcell transplant, especially in the older population, is now being called into question. The ultimate impact of novel agents may be to extend survival in younger patients by achieving CR prior to a single autologous transplant as consolil l dation treatment. The survival of older patients may improve following induction therapy with novel agents without the need for autologous transplant. Further stratification of patients into distinct risk groups based on molecular cytogenetics may also play an important role in deciding treatment options. 40
